The effects of synthetic and endogenous imidazoline binding site ligands on neuronal activity in discrete brain regions of naive and restraint-stressed rats

European Neuropsychopharmacology

Volumn 19, Issue 5, 2009, Pages 371-380

  Smith, Karen L ^a   Roche, Michelle ^a   Jessop, David S ^b   Finn, David P ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Brain; c Fos; Imidazoline binding sites; Limbic system; Rat; Restraint stress

Indexed keywords

2 (2 IMIDAZOLIN 2 YL)QUINOLINE; ALPHA 1 ADRENERGIC RECEPTOR; CORTICOTROPIN RELEASING FACTOR; HARMAN; IMIDAZOLINE; PROTEIN FOS;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANTERIOR HYPOTHALAMUS; ARTICLE; BEHAVIOR CHANGE; BINDING SITE; BRAIN REGION; CATECHOLAMINE NERVE CELL; CONTROLLED STUDY; DENTATE GYRUS; DOSE RESPONSE; DRUG EFFECT; IMMUNOREACTIVITY; MALE; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STRESS;

ANIMALS; BINDING SITES; CORTICOTROPIN-RELEASING HORMONE; HARMINE; IMIDAZOLES; IMIDAZOLINES; MALE; NEURONS; NEUROTOXINS; ONCOGENE PROTEINS V-FOS; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RESTRAINT, PHYSICAL; STRESS, PSYCHOLOGICAL; TYROSINE 3-MONOOXYGENASE;

EID: 62849120059     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.01.005     Document Type: Article

References (62)

1. Ableitner A., and Herz A. Changes in local cerebral glucose utilization induced by the beta-carbolines FG 7142 and DMCM reveal brain structures involved in the control of anxiety and seizure activity. J. Neurosci. 7 (1987) 1047-1055
2. al-Damluji S. Adrenergic mechanisms in the control of corticotrophin secretion. J. Endocrinol. 119 (1988) 5-14
3. Albores R., Neafsey E.J., Drucker G., Fields J.Z., and Collins M.A. Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 9368-9372
4. Anderson N.J., NDJ, Hudson A.L., and Robinson E.S.J. c-fos activation in rat brain following administration of imidazoline binding site and monoamine oxidase ligands. J. Psychopharmacol. 19 (2005) A38 Supplement
5. Anderson N.J., Seif I., Nutt D.J., Hudson A.L., and Robinson E.S. Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. J. Neurochem. 96 (2006) 1551-1559
6. Aricioglu F., and Altunbas H. Harmane induces anxiolysis and antidepressant-like effects in rats. Ann. N. Y. Acad. Sci. 1009 (2003) 196-201
7. Atlas D. Identifying clonidine-displacing substance. Science 266 (1994) 462-464
8. Bour S., Iglesias-Osma M.C., Marti L., Duro P., Garcia-Barrado M.J., Pastor M.F., Prevot D., Visentin V., Valet P., Moratinos J., and Carpene C. The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes. Eur. J. Pharmacol. 552 (2006) 20-30
9. Calogero A.E. Neurotransmitter regulation of the hypothalamic corticotropin-releasing hormone neuron. Ann. N. Y. Acad. Sci. 771 (1995) 31-40
10. Carpene C., Collon P., Remaury A., Cordi A., Hudson A., Nutt D., and Lafontan M. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites. J. Pharmacol. Exp. Ther. 272 (1995) 681-688
11. Chowdhury G.M., Fujioka T., and Nakamura S. Induction and adaptation of Fos expression in the rat brain by two types of acute restraint stress. Brain. Res. Bull. 52 (2000) 171-182
12. Crane J.W., French K.R., and Buller K.M. Patterns of neuronal activation in the rat brain and spinal cord in response to increasing durations of restraint stress. Stress 8 (2005) 199-211
13. Cullinan W.E., Herman J.P., Battaglia D.F., Akil H., and Watson S.J. Pattern and time course of immediate early gene expression in rat brain following acute stress. Neuroscience 64 (1995) 477-505
14. Cummings S., Hinds D., and Young III W.S. Corticotropin-releasing factor mRNA increases in the inferior olivary complex during harmaline-induced tremor. Brain. Res. 660 (1994) 199-208
15. Cunningham Jr. E.T., and Sawchenko P.E. Anatomical specificity of noradrenergic inputs to the paraventricular and supraoptic nuclei of the rat hypothalamus. J. Comp. Neurol. 274 (1988) 60-76
16. De Goeij D.C., Dijkstra H., and Tilders F.J. Chronic psychosocial stress enhances vasopressin, but not corticotropin-releasing factor, in the external zone of the median eminence of male rats: relationship to subordinate status. Endocrinology 131 (1992) 847-853
17. Finn D.P., Lalies M.D., Harbuz M.S., Jessop D.S., Hudson A.L., and Nutt D.J. Imidazoline(2) (I(2)) binding site- and alpha(2)-adrenoceptor-mediated modulation of central noradrenergic and HPA axis function in control rats and chronically stressed rats with adjuvant-induced arthritis. Neuropharmacology 42 (2002) 958-965
18. Finn D.P., Jhaveri M.D., Beckett S.R., Roe C.H., Kendall D.A., Marsden C.A., and Chapman V. Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 45 (2003) 594-604
19. Finn D.P., Marti O., Harbuz M.S., Valles A., Belda X., Marquez C., Jessop D.S., Lalies M.D., Armario A., Nutt D.J., and Hudson A.L. Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology (Berl) 167 (2003) 195-202
20. Finn D.P., Hudson A.L., Kinoshita H., Coventry T.L., Jessop D.S., Nutt D.J., and Harbuz M.S. Imidazoline2 (I2) receptor- and alpha2-adrenoceptor-mediated modulation of hypothalamic-pituitary-adrenal axis activity in control and acute restraint stressed rats. J. Psychopharmacol. 18 (2004) 47-53
21. Garcia-Sevilla J.A., Escriba P.V., Sastre M., Walzer C., Busquets X., Jaquet G., Reis D.J., and Guimon J. Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims. Arch. Gen. Psychiatry. 53 (1996) 803-810
22. Garcia-Sevilla J.A., Escriba P.V., and Guimon J. Imidazoline receptors and human brain disorders. Ann. N. Y. Acad. Sci. 881 (1999) 392-409
23. Gillies G.E., Linton E.A., and Lowry P.J. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 23 299 (1982) 355-357 (5881)
24. Granata A.R. Effect of moxonidine on putative sympathetic neurons in the rostral ventrolateral medulla of the rat. Neurosignals 13 (2004) 241-247
25. Gundlach A.L., Burazin T.C.D., and Louis W.J. Effects of imidazoline drugs on early response gene activity in brain, kidney and adrenal gland. Eur. Neuropsychopharmacol. 6 (1996) 196
26. Hajos M., Fleishaker J.C., Filipiak-Reisner J.K., Brown M.T., and Wong E.H. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS. Drug. Rev. 10 (2004) 23-44
27. Herman J.P., and Cullinan W.E. Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends. Neurosci. 20 (1997) 78-84
28. Holt A., Wieland B., and Baker G.B. Allosteric modulation of semicarbazide-sensitive amine oxidase activities in vitro by imidazoline receptor ligands. Br. J. Pharmacol. 143 (2004) 495-507
29. Hudson A.L., Gough R., Tyacke R., Lione L., Lalies M., Lewis J., Husbands S., Knight P., Murray F., Hutson P., and Nutt D.J. Novel selective compounds for the investigation of imidazoline receptors. Ann. N. Y. Acad. Sci. 881 (1999) 81-91
30. Kalin N.H., Shelton S.E., and Turner J.G. Effects of beta-carboline on fear-related behavioral and neurohormonal responses in infant rhesus monkeys. Biol. Psychiatry. 31 (1992) 1008-1019
31. Kim H., Sablin S.O., and Ramsay R.R. Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch. Biochem. Biophys. 337 (1997) 137-142
32. King P.R., Gundlach A.L., and Louis W.J. Quantitative autoradiographic localization in rat brain of alpha 2-adrenergic and non-adrenergic I-receptor binding sites labelled by [3H]rilmenidine. Brain. Res. 675 (1995) 264-278
33. Lione L.A., Nutt D.J., and Hudson A.L. Characterisation and localisation of [3H]2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I2 receptors. Eur. J. Pharmacol. 353 (1998) 123-135
34. Liposits Z., Phelix C., and Paull W.K. Adrenergic innervation of corticotropin releasing factor (CRF)-synthesizing neurons in the hypothalamic paraventricular nucleus of the rat. A combined light and electron microscopic immunocytochemical study. Histochemistry 84 (1986) 201-205
35. MacInnes N., and Handley S.L. Autoradiographic localisation of [3H]2-BFI imidazoline I2 binding sites in mouse brain. Eur. J. Pharmacol. 516 (2005) 139-144
36. Macrae I.M., and Browne S.E. Brain structures involved in the hypotensive effects of rilmenidine: evaluation by [14C]2-deoxyglucose autoradiography. J. Cardiovasc. Pharmacol. 26 Suppl 2 (1995) S55-58
37. Mallard N.J., Hudson A.L., and Nutt D.J. Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain. Br. J. Pharmacol. 106 (1992) 1019-1027
38. Musgrave I.F., and Badoer E. Harmane produces hypotension following microinjection into the RVLM: possible role of I(1)-imidazoline receptors. Br. J. Pharmacol. 129 (2000) 1057-1059
39. Nutt D.J., French N., Handley S., Hudson A., Husbands S., Jackson H., Jordan S., Lalies M.D., Lewis J., Lione L., et al. Functional studies of specific imidazoline-2 receptor ligands. Ann. N. Y. Acad. Sci. 763 (1995) 125-139
40. Parker C.A., Anderson N.J., Robinson E.S., Price R., Tyacke R.J., Husbands S.M., Dillon M.P., Eglen R.M., Hudson A.L., Nutt D.J., Crump M.P., and Crosby J. Harmane and harmalan are bioactive components of classical clonidine-displacing substance. Biochemistry 43 (2004) 16385-16392
41. Paterson L.M., Tyacke R.J., Robinson E.S., Nutt D.J., and Hudson A.L. In vitro and in vivo effect of BU99006 (5-isothiocyanato-2-benzofuranyl-2-imidazoline) on I2 binding in relation to MAO: evidence for two distinct I2 binding sites. Neuropharmacology 52 (2007) 395-404
42. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 4th edition (1998), Elsevier, San Diego edn
43. Piletz J.E., Halaris A., Nelson J., Qu Y., and Bari M. Platelet I1-imidazoline binding sites are elevated in depression but not generalized anxiety disorder. J. Psychiatr. Res. 30 (1996) 147-168
44. Piletz J.E., Halaris A.E., Chikkala D., and Qu Y. Platelet I1-imidazoline binding sites are decreased by two dissimilar antidepressant agents in depressed patients. J. Psychiatr. Res. 30 (1996) 169-184
45. Piletz J., Baker R., and Halaris A. Platelet imidazoline receptors as state marker of depressive symptomatology. J. Psychiatr. Res. 42 (2008) 41-49
46. Plotsky P.M. Facilitation of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation after activation of catecholaminergic pathways or central norepinephrine injection. Endocrinology 121 (1987) 924-930
47. Pratt J.A., Laurie D.J., and McCulloch J. The effects of FG 7142 upon local cerebral glucose utilization suggest overlap between limbic structures important in anxiety and convulsions. Brain. Res. 475 (1988) 218-231
48. Priou A., Oliver C., and Grino M. In situ hybridization of arginine vasopressin (AVP) heteronuclear ribonucleic acid reveals increased AVP gene transcription in the rat hypothalamic paraventricular nucleus in response to emotional stress. Acta. Endocrinol. (Copenh). 128 (1993) 466-472
49. Raddatz R., and Lanier S.M. Relationship between imidazoline/guanidinium receptive sites and monoamine oxidase A and B. Neurochem. Int. 30 (1997) 109-117
50. Rivier C., and Vale W. Interaction of corticotropin-releasing factor and arginine vasopressin on adrenocorticotropin secretion in vivo. Endocrinology 113 (1983) 939-942
51. Roche M., Harkin A., and Kelly J.P. Chronic fluoxetine treatment attenuates stressor-induced changes in temperature, heart rate, and neuronal activation in the olfactory bulbectomized rat. Neuropsychopharmacology 32 (2007) 1312-1320
52. Romero L.M., Plotsky P.M., and Sapolsky R.M. Patterns of adrenocorticotropin secretagogue release with hypoglycemia, novelty, and restraint after colchicine blockade of axonal transport. Endocrinology 132 (1993) 199-204
53. Rommelspacher H., May T., and Salewski B. Harman (1-methyl-beta-carboline) is a natural inhibitor of monoamine oxidase type A in rats. Eur. J. Pharmacol. 252 (1994) 51-59
54. Ruiz-Durantez E., Ruiz-Ortega J.A., Pineda J., and Ugedo L. Stimulatory effect of harmane and other beta-carbolines on locus coeruleus neurons in anaesthetized rats. Neurosci. Lett. 308 (2001) 197-200
55. Saczewski F., Tabin P., Tyacke R.J., Maconie A., Saczewski J., Kornicka A., Nutt D.J., and Hudson A.L. 2-(4,5-Dihydroimidazol-2-yl)benzimidazoles as highly selective imidazoline I2/adrenergic alpha2 receptor ligands. Bioorg. Med. Chem. 14 (2006) 6679-6685
56. Sarter M. Elevations of local cerebral glucose utilization by the beta-carboline ZK 93426. Eur. J. Pharmacol. 177 (1990) 155-162
57. Schule C. Neuroendocrinological mechanisms of actions of antidepressant drugs. J. Neuroendocrinol. 19 (2007) 213-226
58. Talalaenko A.N., Krivobok G.K., Pankrat′ev D.V., and Goncharenko N.V. Neurochemical mechanisms of the dorsal pallidum in the antiaversive effects of anxiolytics in various models of anxiety. Neurosci. Behav. Physiol. 36 (2006) 749-754
59. Tesson F., Limon-Boulez I., Urban P., Puype M., Vandekerckhove J., Coupry I., Pompon D., and Parini A. Localization of I2-imidazoline binding sites on monoamine oxidases. J. Biol. Chem. 270 (1995) 9856-9861
60. Ugedo L., Pineda J., Ruiz-Ortega J.A., and Martin-Ruiz R. Stimulation of locus coeruleus neurons by non-I1/I2-type imidazoline receptors: an in vivo and in vitro electrophysiological study. Br. J. Pharmacol. 125 (1998) 1685-1694
61. Whitnall M.H. Stress selectively activates the vasopressin-containing subset of corticotropin-releasing hormone neurons. Neuroendocrinology 50 (1989) 702-707
62. Zhou J. Norepinephrine transporter inhibitors and their therapeutic potential. Drugs Future 29 (2004) 1235-1244